Company Profile

Bayhill Therapeutics Inc (AKA: Tolerion Inc)
Profile last edited on: 3/15/19      CAGE:       UEI:

Business Identifier: Developing drugs to restore immune system
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3400 West Bayshore Road
Palo Alto, CA 94303
   (650) 846-4800
Location: Single
Congr. District: 18
County: Santa Clara

Public Profile

Orihinal doing business as Tolerion, Inc. and organzied around vaccines to treat autoimmune diseases, in late 2002, the firm was renamed Bayhill Therapeutics, Inc. shifting its focus to autoimmune and metabolic diseases. The firm fell victim to the 2008 recession when management attempted an IPO but had to withdraw. At it height, Bayhill Thereapeutics was at the forefront of developing novel and targeted treatment candidates for autoimmune diseases. Leveraging its proprietary therapeutic BHT-DNA™ platform, the Company’s product candidates were designed to restore a patient’s immune system “tolerance” to self antigens to its normal state by selectively eliminating specific, harmful immune responses while leaving the rest of the immune system intact. Through a targeted and selective approach, Bayhill’s product candidates had the potential to deliver superior efficacy, safety and tolerability relative to current therapies. Though it was later recorded that the firm was winding down its operations but that assets were acquired by a reincarnation, it is not apparent whether th

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2002 1 NIH $100,000
Project Title: DNA Tolerizing Vaccine Therapy for Multiple Sclerosis

Key People / Management

  Lawrence Steinman -- President

  Hideki Garren -- Founder COO and CSO

Company News

There are no news available.